This three-part episode follows a discussion of the current state of HCT by exploring its evolution over time. Fred Appelbaum, MD, of Fred Hutchinson Cancer Center, and Courtney Bellomo, MD, of New York Oncology Hematology lead the discussion. In Part 2: Donor Availability, Graft Sources and the Birth of NMDP, they discuss how unrelated donor availability and alternative stem cell sources have substantially increased access to HCT. They share the story of the first unrelated donor transplant for leukemia, performed at Fred Hutch in 1979, and how it led to the development of the NMDP/Be The Match Registry. For more information, resources from the episode, or full bios of our guests, visit our site.